Fujian Wanchen Biotechnology Group Balance Sheet Health
Financial Health criteria checks 5/6
Fujian Wanchen Biotechnology Group has a total shareholder equity of CN¥1.2B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 105.2%. Its total assets and total liabilities are CN¥6.5B and CN¥5.3B respectively. Fujian Wanchen Biotechnology Group's EBIT is CN¥648.2M making its interest coverage ratio 15.7. It has cash and short-term investments of CN¥2.3B.
Key information
105.2%
Debt to equity ratio
CN¥1.25b
Debt
| Interest coverage ratio | 15.7x |
| Cash | CN¥2.29b |
| Equity | CN¥1.19b |
| Total liabilities | CN¥5.27b |
| Total assets | CN¥6.46b |
Recent financial health updates
Recent updates
Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality
Nov 04
Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company
Oct 01Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing
Sep 30We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt
Aug 04Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)
Jun 06Financial Position Analysis
Short Term Liabilities: 300972's short term assets (CN¥4.9B) exceed its short term liabilities (CN¥4.6B).
Long Term Liabilities: 300972's short term assets (CN¥4.9B) exceed its long term liabilities (CN¥680.6M).
Debt to Equity History and Analysis
Debt Level: 300972 has more cash than its total debt.
Reducing Debt: 300972's debt to equity ratio has increased from 64.2% to 105.2% over the past 5 years.
Debt Coverage: 300972's debt is well covered by operating cash flow (164%).
Interest Coverage: 300972's interest payments on its debt are well covered by EBIT (15.7x coverage).